| P50 | author | Ignacio Duran | Q60068308 |
| P2093 | author name string | Alfonso Gómez De Liaño | |
| P2860 | cites work | Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma | Q27024948 |
| | Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 |
| | Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma | Q88148484 |
| | EMA restricts use of anti-PD-1 drugs for bladder cancer | Q89054721 |
| | Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder | Q90703106 |
| | Molecular Subtypes of Bladder Cancer | Q91055639 |
| | Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium | Q93606365 |
| | Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy | Q44673128 |
| | Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). | Q45760907 |
| | Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. | Q46035514 |
| | Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study | Q46174958 |
| | Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial | Q46287609 |
| | A Phase II study of oxaliplatin in urothelial cancer | Q46501921 |
| | Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment | Q46597676 |
| | Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 |
| | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial | Q47264823 |
| | Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes | Q47562662 |
| | Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. | Q47568177 |
| | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. | Q47717093 |
| | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial | Q47767940 |
| | Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer | Q47974667 |
| | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Q50001757 |
| | Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. | Q50104337 |
| | A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). | Q50719940 |
| | Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. | Q50719954 |
| | PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. | Q51799211 |
| | Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. | Q51939874 |
| | SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. | Q52609425 |
| | Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. | Q52681588 |
| | Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled | Q52882813 |
| | Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. | Q53263269 |
| | Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. | Q53462584 |
| | Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. | Q53584625 |
| | Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. | Q53592801 |
| | Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. | Q53662109 |
| | Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). | Q53681746 |
| | Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis | Q56335809 |
| | Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations | Q56567688 |
| | Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group | Q57949258 |
| | Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial | Q59629290 |
| | A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 |
| | Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | Q69401186 |
| | M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience | Q69654530 |
| | Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study | Q71067477 |
| | Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy | Q73042239 |
| | Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 |
| | Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma | Q73872746 |
| | Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European | Q73881573 |
| | Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer | Q77639607 |
| | Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function | Q79479624 |
| | Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium | Q79899307 |
| | Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience | Q80201185 |
| | Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer | Q80785289 |
| | Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy | Q86151894 |
| | Chemotherapy of urothelial tract tumors | Q39657948 |
| | Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens | Q39891466 |
| | Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin | Q39974237 |
| | Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group | Q40446162 |
| | Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. | Q40482977 |
| | A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium | Q40635141 |
| | Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group | Q40636458 |
| | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer | Q40715310 |
| | A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 |
| | Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma | Q40905847 |
| | A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma | Q41237750 |
| | The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer | Q41709315 |
| | Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). | Q41728002 |
| | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. | Q41979947 |
| | Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy | Q42508303 |
| | Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer | Q42516513 |
| | Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. | Q42697376 |
| | Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 |
| | Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy | Q43542810 |
| | Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate | Q43715235 |
| | Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. | Q43733824 |
| | A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer | Q43777231 |
| | Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma | Q43788672 |
| | Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life | Q43917659 |
| | New insights into subtypes of invasive bladder cancer: considerations of the clinician | Q43988194 |
| | Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy | Q44578641 |
| | Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract | Q34997941 |
| | Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy | Q35076309 |
| | Review of a promising new agent--pemetrexed disodium | Q35097974 |
| | SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma | Q35540039 |
| | Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations | Q35864528 |
| | Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial | Q35939674 |
| | A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B | Q36115630 |
| | Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 |
| | Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter | Q36116031 |
| | Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. | Q36235936 |
| | Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer | Q36608587 |
| | Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer | Q36612596 |
| | A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen | Q36614243 |
| | Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. | Q36615090 |
| | Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) | Q36627206 |
| | Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy | Q36953563 |
| | Urothelial carcinoma management in elderly or unfit patients | Q37030514 |
| | A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. | Q37200497 |
| | Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study | Q37523616 |
| | Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. | Q37873687 |
| | New treatments for bladder cancer: when will we make progress? | Q38177753 |
| | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. | Q38372019 |
| | Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. | Q38400656 |
| | DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma | Q38764205 |
| | Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker | Q38788799 |
| | Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. | Q38840461 |
| | Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study | Q38855950 |
| | Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis. | Q38881827 |
| | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study | Q39084242 |
| | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Q39107888 |
| | Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review | Q39210427 |
| | Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). | Q39303051 |
| | DNA Damage and Repair Biomarkers of Immunotherapy Response | Q39384263 |
| | Biomarkers of response to PD-1/PD-L1 inhibition. | Q39426306 |
| | Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 |
| | A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 |
| | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 |
| | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Q30275266 |
| | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 |
| | Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study | Q33329178 |
| | Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group | Q33330628 |
| | Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial | Q33331273 |
| | Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function | Q33333141 |
| | Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. | Q33334087 |
| | Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study | Q33335472 |
| | Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. | Q33340282 |
| | Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens | Q33344322 |
| | Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group | Q33362483 |
| | Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). | Q33369889 |
| | Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium | Q33371986 |
| | Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group | Q33372629 |
| | M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience | Q33376563 |
| | Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. | Q33394575 |
| | Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 | Q33398722 |
| | Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. | Q33399928 |
| | Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma | Q33411581 |
| | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Q33435967 |
| | Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 |
| | Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 |
| | A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium | Q33497225 |
| | Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 |
| | Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 |
| | A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 |
| | Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy | Q33572016 |
| | Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer | Q33923405 |
| | Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells | Q34193379 |
| | Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. | Q34438928 |
| | Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models | Q34519750 |
| P433 | issue | 12 | |
| P921 | main subject | chemotherapy | Q974135 |
| | urology | Q105650 |
| P304 | page(s) | 455-480 | |
| P577 | publication date | 2018-11-28 | |
| P1433 | published in | Therapeutic advances in urology | Q26842184 |
| P1476 | title | The continuing role of chemotherapy in the management of advanced urothelial cancer | |
| P478 | volume | 10 | |